期刊文献+

BCNU缓释微球体内外释放与分布 被引量:4

In vitro and in vivo release and disposition of BCNU sustained release microspheres
在线阅读 下载PDF
导出
摘要 目的探讨自制卡氮芥(BCNU)聚乳酸-羟基乙酸(PLGA)缓释微球的体内外药物释放过程以及在大鼠脑组织的分布与其生物相容性。方法应用高效液相色谱法检测BCNU在磷酸盐缓冲溶液和脑组织内自聚乳酸.羟基乙酸缓释微球释放的药物含量;应用3H标记BCNU,检测3H—BCNU缓释微球在正常大鼠脑组织及血清中的分布;BCNU缓释微球植入大鼠脑组织,常规HE染色,光镜下观察其生物相容性。结果BCNU-PLGA-MS在PBS和大鼠脑组织中均可持续释放药物2周以上;缓释剂植入侧脑组织药物浓度比对侧高6.70倍;大鼠脑组织表现为小胶质细胞反应。结论BCNU—PLGA缓释微球具有良好的缓释功能,而且安全性、生物相容性较好。 Objective To explore the in vitro and in vivo course of BCNU released from BCNU-loaded PLGA mierospheres and location in rat brain tissue. Methods The concentrations of BCNU in PBS and brain tissue were determined by high performance liquid chromatography, and 3H-labeled BCNU was used to determine the location in normal brain tissue and serum. The biocompatibility of mierospheres was evaluated by the routine HE stain. Results The BCNU could be sustained released from BCNU-PLGA-MS over 2 weeks both in PBS and in brain tissue, and the concentrations of BCNU in ipsilateral side was 6 to 70 times higher than those in eontralateral. The rat brain tissue demonstrated gIial cell reaction. Conclusion BCNU-PLGA sustained release microspheres are safe and biocompatible.
出处 《临床神经外科杂志》 CAS 2007年第1期27-30,共4页 Journal of Clinical Neurosurgery
关键词 BCNU PLGA 释放动力学 分布 生物相容性 BCNU PLGA released kinetics disposition biocompatibility
  • 相关文献

参考文献12

  • 1[1]Zhu K-J,Jiang H-L,Du X-Y,et al.Preparation and characterization of hCG-loaded polylactide or poly(lactide-co-glycolide)microspheres using a modified water-in-oil-in-water(w/o/w)emulsion solvent evaporation technique[J].J Microencapsul,2001,18:247.
  • 2[2]Wang J,Wang BM,Schwen deman SP.Characterization of the initial burst release of a model peptide from poly(d,l-lactide-co-glycolide)microspheres[J].J Control Release,2002,82:289.
  • 3[3]Takenaga M,Yamaguehi Y,Kitagawa A,et al.A novel sustained-release formulation of insulin with dramatic reduction ininitial rapid release[J].J Control Release,2002,79:81.
  • 4[4]Pamujula,S,Graves R A,Kishore,-V.Preparation and in vitro characterization of amifostine biodegradable microcapsules[J].Eur J Pharm Biopharm,2004,57:213.
  • 5[5]Filipovic Grcic,Crc,-V,Jalsenjak,I.Albumin-loaded PLA and PLGA microspheres:in vitro evaluation[J].Boll Chim Farm,1999,138:14.
  • 6[6]Ueda,M;Iwara,A;Kreuter J.Influence of the preparation methods on the drug release behaviour of loperamide-loaded nanoparticles[J].J Microeneapsul,1998,15:361.
  • 7[7]Bridges,J F;Critchlow M;Iring M P.Radiolabeling,stability,and body distribution in rats,of low molecular weight polylactide homopolymer and polylactide-polyethyleneglycol copolymer[J].Biomaterials,2002,21:199.
  • 8[8]Le-Corre,P Rytting,J H,Gajan V.In vitro controlled release kinetics of local anaesthetics from poly(D,L-lactide)and poly(lactide-co-glycolide)micrespheres[J].J Microencapsul,1997,14:243.
  • 9[9]Wang FJ,Wang CH.Sustained release of etanidazole from spray dried microspheres prepared by non-halo-genatedsolvents[J].J Control Release,2002,81:263.
  • 10[10]Faisant N,Siepmann J,Benoit JP.PLGA-based micreparticles:elucidation of mechanisms and a new,simple mathematical model quantifying drug release[J].Eur J Pharm Sci,1002,15:355.

同被引文献32

  • 1赵时雨,袁先厚,江普查,李志强,郭国炳.复发性脑胶质瘤再手术并瘤腔内化疗临床研究[J].中华神经外科疾病研究杂志,2005,4(1):77-78. 被引量:8
  • 2Lynn S Ashby(著),Timothy C Ryken(著),刘暌(译),只达石(校).恶性胶质瘤的治疗:综合方案的进展[J].中国现代神经疾病杂志,2006,6(6):453-458. 被引量:8
  • 3汤宇,尹维斌,李朝兴,王镇.聚[1,3-双(对羧基苯氧基)丙烷-癸二酸](20:80)-替莫唑胺长效缓释微球的制备及药物缓释性能的研究[J].离子交换与吸附,2006,22(6):565-570. 被引量:4
  • 4赵红军,许红旗.脑胶质瘤BCNU治疗方法的对比研究[J].临床外科杂志,2007,15(4):268-269. 被引量:3
  • 5[1]NEWLANDS E S,STEVENS M F,WEDGE S R,et al.Temozolomide:a review of its discovery,chemical properties,pre-clinical development and clinical trials[J].Cancer Treat Rev,1997,23(1):35-61.
  • 6[5]WESTPHAL M,HILT D C,BORTEY E,et al.A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma[J].Neuro Oncol,2003,5(2):79-88.
  • 7[9]ZHANG H,GAO S.Temozolomide/PLGA microparticles and antitumor activity against glioma C6 cancer cell in vitro[J].Int J Pharm,2007,329(1-2):122-128.
  • 8[10]RENI M,MASON W,ZAJA F,et al.Salvage chemotherapy with temozolomide in primary CNS iymphomas:preliminary results of a phase Ⅱ trial[J].Eur J Cancer,2004,40(11):1682-1688.
  • 9[11]FLEMING A B,SALTZMAN W M,et al.Pharmacokinetics of the carmustine implant[J].Clin Pharmacokinet,2002,41(6):403-419.
  • 10Maes W, Van Goal SW. Experimental immunotherapy for malignant glioma: lessons from two decades of research in the GL261 model.[J]. Cancer Immunol Immunother,2011,60 :153.

引证文献4

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部